We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Acute Myeloid Leukemia Regulatory Networks Identified

By LabMedica International staff writers
Posted on 28 Nov 2018
Print article
Image: A bone marrow smear of a patient with Acute Myeloid Leukemia; dysplastic changes are noted in both the granulocytic and erythroid lineages (Photo courtesy of Peter Maslak).
Image: A bone marrow smear of a patient with Acute Myeloid Leukemia; dysplastic changes are noted in both the granulocytic and erythroid lineages (Photo courtesy of Peter Maslak).
Adult acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes abnormal myeloblasts (a type of white blood cell), red blood cells, or platelets. AML is a heterogeneous disease caused by a variety of alterations in transcription factors, epigenetic regulators and signaling molecules.

Through an integrated analysis of purified leukemic blast cells, scientists have analyzed transcriptional networks in dozens of AML cases, along with the cis-regulatory element alterations coinciding with them. The findings highlighted ties between transcriptomic and epigenomic features that correspond to specific transcription factor, signaling molecule, or nuclear protein gene mutations in AML.

A team of scientists at the University of Birmingham (Birmingham, UK) and their colleagues determined how different mutant regulators establish AML subtype–specific transcriptional networks, and performed a comprehensive global analysis of cis-regulatory element activity and interaction, transcription factor occupancy and gene expression patterns in purified leukemic blast cells.

The team focused on specific subgroups of subjects carrying mutations in genes encoding transcription factors: Runt-related transcription factor 1 (RUNX1), and CCAAT-enhancer binding protein alpha (CEBPα); signaling molecules: fms-like tyrosine kinase 3- Internal Tandem Duplication (FLT3-ITD), and RAS, and the nuclear protein nucleophosmin (NPM1). Integrated analysis of these data demonstrates that each mutant regulator establishes a specific transcriptional and signaling network unrelated to that seen in normal cells, sustaining the expression of unique sets of genes required for AML growth and maintenance.

The team performed transcriptomic analyses, chromatin conformation capture profiling, and digital footprinting in leukemic blast cells from AML cases with specific transcription factor or signaling gene mutations identified with targeted sequencing on 55 cancer-related genes. In particular, the team incorporated RNA sequence data and open chromatin-mapping DNase I sequence from 29 purified leukemic blast samples from bone marrow or peripheral blood samples in AML cases involving a series of distinct mutations, including several distinct RUNX1 alterations. Along with promoter cis-regulatory element interaction profiles and data for a dozen samples assessed with at least one genomic approach, the data revealed transcriptome, chromatin, transcription factor occupancy, and regulatory clusters that coincided with specific AML mutation subsets.

Constanze Bonifer, PhD, a professor and co-senior author of the study, said, “Crucially, AML cells from patients with the same types of mutations always take the same route when they head off in the wrong direction. Our analyses of each of the pathways that the cells took when developing into cancer identified key points in the cell that could be used in the future to target and develop new drugs to treat each type of AML in a different way.” The study was published on November 12, 2018, in the journal Nature Genetics.

Related Links:
University of Birmingham

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.